Castle Biosciences Posts 37% Test Volume Growth Amid Strategic Shifts
Event summary
- Castle Biosciences reported 37% year-over-year growth in test volumes for its core revenue drivers, DecisionDx-Melanoma and TissueCypher, in 2025.
- Full-year 2025 revenue reached $344.2 million, a 4% increase from 2024, but excluding discontinued tests, growth was 34%.
- The company launched AdvanceAD-Tx, expanding its addressable market in dermatology.
- Net loss for 2025 was $24.2 million, compared to a net income of $18.2 million in 2024.
- Cash reserves stood at $299.5 million as of December 31, 2025.
The big picture
Castle Biosciences' 2025 results highlight its strategic pivot towards non-dermatologic tests and the launch of AdvanceAD-Tx, which could diversify its revenue streams. The company's ability to navigate regulatory and market dynamics will be crucial as it aims to capitalize on its expanded addressable market. With a strong cash position, Castle Biosciences is well-positioned to invest in growth, but it must address declining margins to maintain investor confidence.
What we're watching
- Revenue Diversification
- Whether Castle Biosciences can sustain growth in non-dermatologic tests, which contributed $127.9 million in 2025, up from $75.1 million in 2024.
- Market Expansion
- The pace at which AdvanceAD-Tx gains traction in the atopic dermatitis market, potentially expanding the company's total addressable market.
- Operational Efficiency
- How the company will manage its gross margin, which declined to 69% in 2025 from 79% in 2024, amid strategic shifts and discontinued tests.
Related topics